Close Menu

Epitomics

Aushon Biosystems has launched Cira, its new multiplex immunoassay platform.

Bio-Rad this week introduced its V3 Western Workflow, a portfolio of products for Western blotting that include its TGX Stain-Free gels, ChemiDox MP imaging system, and TransBlot Turbo transfer system.

Epitomics has released new rabbit monoclonal antibodies for a variety of proteins including phospho LRRK2, TTF1, CHx10, and LSD1.

NanoInk this week released its new NanoArray Assay System for the automated analysis of its protein NanoArray assays.

The company, called SISCAPA Assay Technologies, will offer assay development to pharmas and CROs and has tapped antibody firm Epitomics to produce reagents for the system and sell SISCAPA kits. So far, the company has licensed the technology to Pfizer for internal use.

The work will focus on developing antibodies to tryptic peptides derived from protein biomarkers in human plasma for mass spec workflows like SISCAPA and immuno-MALDI.

Under its contract with SAIC-Frederick, Epitomics will develop high affinity and renewable agents to capture tryptic peptides derived from human plasma protein biomarkers.

The UK and the European Union have come to a sticking point in the negotiation of how the UK might remain involved in the Horizon Europe research program, the Guardian reports.

The New York Times reports that experts pushed during a meeting of an FDA advisory board for the agency to require more safety data from SARS-CoV-2 vaccine trials.

The Washington Post reports Moderna expects that it will have enough data on its candidate SARS-CoV-2 vaccine to submit to regulatory authorities by mid-November.

In Science this week: ANXA11 variants affect calcium homeostasis and stress granule disassembly in ALS, and more.